Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
This study has been completed.
Sponsor:
Immunomedics, Inc.
Information provided by (Responsible Party):
Immunomedics, Inc.
ClinicalTrials.gov Identifier:
NCT00603668
First received: January 8, 2008
Last updated: March 25, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | February 2013 |
| Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |